Adverum Biotechnologies Inc (ADVM)
6.02
+0.27
(+4.70%)
USD |
NASDAQ |
Nov 22, 14:48
Adverum Biotechnologies Total Assets (Quarterly): 234.38M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 234.38M |
June 30, 2024 | 253.80M |
March 31, 2024 | 267.83M |
December 31, 2023 | 173.01M |
September 30, 2023 | 196.77M |
June 30, 2023 | 241.43M |
March 31, 2023 | 275.58M |
December 31, 2022 | 308.37M |
September 30, 2022 | 332.36M |
June 30, 2022 | 374.96M |
March 31, 2022 | 407.39M |
December 31, 2021 | 439.73M |
September 30, 2021 | 490.58M |
June 30, 2021 | 526.15M |
March 31, 2021 | 461.55M |
December 31, 2020 | 482.57M |
September 30, 2020 | 507.71M |
June 30, 2020 | 331.18M |
March 31, 2020 | 348.60M |
December 31, 2019 | 222.73M |
September 30, 2019 | 205.52M |
June 30, 2019 | 209.88M |
Date | Value |
---|---|
March 31, 2019 | 221.05M |
December 31, 2018 | 213.50M |
September 30, 2018 | 225.91M |
June 30, 2018 | 246.58M |
March 31, 2018 | 257.16M |
December 31, 2017 | 201.90M |
September 30, 2017 | 198.21M |
June 30, 2017 | 208.58M |
March 31, 2017 | 221.93M |
December 31, 2016 | 234.58M |
September 30, 2016 | 256.57M |
June 30, 2016 | 264.34M |
March 31, 2016 | 252.93M |
December 31, 2015 | 264.32M |
September 30, 2015 | 273.83M |
June 30, 2015 | 283.72M |
March 31, 2015 | 292.69M |
December 31, 2014 | 161.91M |
September 30, 2014 | 167.24M |
June 30, 2014 | 54.79M |
March 31, 2014 | 51.61M |
December 31, 2013 | 1.085M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
173.01M
Minimum
Dec 2023
526.15M
Maximum
Jun 2021
343.83M
Average
331.77M
Median
Total Assets (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | 300.92M |
Cassava Sciences Inc | 223.75M |
Regenxbio Inc | 519.11M |
Editas Medicine Inc | 327.57M |
Apellis Pharmaceuticals Inc | 901.87M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 90.26M |
Shareholders Equity (Quarterly) | 144.12M |
Current Ratio | 5.824 |